fbpx

Olema Pharmaceuticals Inc

OLMA

$10.28

Closing

▲1.88%

1D

▼-26.73%

YTD

OLMA

BBG00T5JMRV1

Exchange

Sector

Market cap

$589.02M

Volume

148,448

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$589.02M

Analysts' Rating

BUY

Price Target (Mean)

27.43

Total Analysts

9

P/E

Operating Margin

0.00%

Beta

1.93

Revenue Growth

0.00%

52 week high

$16.75

52 week low

$7.68

Div. Yield

%

EPS Growth

-3.57

Company Profile

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women’s cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company’s OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.